Acute myocardial infarction in a patient with hemophilia A and factor V Leiden mutation

Factor VIII:C, epsilon amino-caproic acid or tranexamic acid are prophylactic agents used in preventing hemorrhage pre-operatively in patients with hemophilia A. Although hemophilia A seems to be a factor that avoids the development of acute myocardial infarction (AMI) as it tends to be associated with increased bleeding, it should be kept in mind that prothrombotic agents used pre-operatively for prophylaxis may increase the risk for AMI in the presence of the factor V Leiden mutation. In this report, we discuss the development of AMI following the use of recombinant factor VIII and tranexamic acid for prophylaxis in a patient with known hemophilia before a tooth extraction in conjunction with the relevant literature

An Unusual Cause of Unilateral Pleural Effusion in the Setting of Aortic Stenosis: Acute Myeloid Leukemia

Pleural effusion has various causes. In the setting of aortic stenosis, new onset pleural effusion is generally considered as a consequence of heart failure. Here, we describe a 50-year-old male patient who had been followed with aortic stenosis for 30 years. During his admission he presented with exertional dyspnea and pleuritic chest pain. He had no other symptoms or findings of cardiac failure. Complete blood count revealed neutrophilic leukocytosis, a normal hemoglobin level and normal platelet count. Left sided pleural effusion was noted on the posteroanterior chest X-ray. Examination of the pleural fluid revealed myeloid blasts. Bone marrow aspiration smear and flow cytometric analysis of the bone marrow and pleural fluid were consistent with acute myeloid leukemia

Acute myocardial infarction in a patient with hemophilia A and factor V Leiden mutation

Factor VIII:C, epsilon amino-caproic acid or tranexamic acid are prophylactic agents used in preventing hemorrhage pre-operatively in patients with hemophilia A. Although hemophilia A seems to be a factor that avoids the development of acute myocardial infarction (AMI) as it tends to be associated with increased bleeding, it should be kept in mind that prothrombotic agents used Pre-operatively for prophylaxis may increase the risk for AMI in the presence of the factor V Leiden mutation. In this report, we discuss the development of AMI following the use of recombinant factor VIII and tranexamic acid for prophylaxis in a patient with known hemophilia before a tooth extraction in conjunction with the relevant literature. (Cardiol J 2009; 16, 5: 458-461

Atypical M-protein localization in protein electrophoresis in a patient with multiple myeloma

Monoclonal gammopathy is a group of B-cell disorders resulting in the secretion of a specific and unique monoclonal immunoglobulin (M-component). The best method for detecting a monoclonal protein is high resolution agarose gel electrophoresis. This test detects abnormalities in the migration of the proteins on electrophoresis and can be performed with samples of serum or urine. An M-protein is usually visible as a localized band on agarose gel electrophoretic peak in the beta, gamma, or rarely in the alpha-2 globulin region of the densitometer tracing. Here, we presented a multiple myeloma patient with IgA kappa paraprotein showing an M spike in the alpha-2 globulin region in agarose gel electrophoresis

Primary pulmonary lymphoma: A report of two cases

Primary lung lymphomas represent less than 1% of all non-Hodgkin's lymphomas, and most of these are MALT (mucosa-associated lymphoid tissue) lymphomas that originate from bronchial mucosa-associated lymphoid tissue. In this report, we presented two cases of primary lung MALT lymphoma whose diagnoses were made by bronchospy and histopathological examination. Initial diagnoses were postobstructive pneumonia unresponsive to antibiotherapy in one patient, and lung carcinoma with persistent cough in the other

A case applied with decompensated heart failure findings diagnosed as primary effusion lymphoma

Primary Effusion Lymphoma (PEL) is an infrequent subtype of Non-Hodgkin's Lymphoma which is characterized by lymphomatous effusions in body cavities, not-associated with mass lesions. Generally PEL is reported in immunocompromised patients infected with human immunodeficiency virus (HIV) and Human Herpes Virus-8 (HHV-8). Recently HIV and HHV-8 negative cases were also reported. Here, we report a 76 year-old man with HIV and HHV-8 negative PEL successfully treated with R-COP chemotherapy protocol

Leukocytoclastic vasculitis due to thalidomide in multiple myeloma

Thalidomide is successfully used in the treatment of multiple myeloma, leprosy and various autoimmune diseases due to its anti-angiogenic, immunomodulatory and anti-inflammatory effects. Thalidomide's most common side effects are constipation, neuropathy, fatigue, sedation, rash, tremor and peripheral edema. We achieved complete responce with a 400 mg/day dose thalidomide therapy in a 58-year-old male patient diagnosed with relapsing refractory multiple myeloma. While continuing thalidomide for sustainable response, the therapy was terminated at the ninth month due to development of leukocytoclastic vasculitis. We describe the case and discuss the place of thalidomide in the treatment of multiple myeloma and the rare occurrence of leukocytoclastic vasculitis during thalidomide therapy in multiple myeloma, since only one such case has been reported in the literature thus far

CLINICAL FOLLOW-UP AND TREATMENT RESPONSE OF THE 162 PATIENTS WITH CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA

Aim: In this report, we investigated the presenting clinical features, therapy indications, clinical follow-up and treatment results of the 162 patients with chronic idiopathic thrombocytopenic purpura (ITP)